Seneste forsøg


EudraCT Number: 2004-000715-26 Sponsor Protocol Number: BO17920 Start Date: 2005-02-02
Sponsor Name: F. Hoffmann-La Roche Ltd.
Full Title: A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Le...
Medical condition: Adjuvant treatment for patients who have undergone surgery for Colon cancer, AJCC/UICC high-risk Stage II & stage III
Disease: Version SOC Term Classification Code Term Level
7 10009954 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FI (Completed) SE (Completed) DE (Completed) HU (Completed) GB (Completed) CZ (Completed) ES (Completed) IT (Completed)
Trial results: View results

EudraCT Number: 2004-004249-16 Sponsor Protocol Number: F02207GE204 Start Date: 2005-02-02
Sponsor Name: PIERRE FABRE MEDICAMENT
Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY
Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: GB (Completed) SE (Completed) DE (Completed)
Trial results: View results
EudraCT Number: 2004-002925-39 Sponsor Protocol Number: 040826 Start Date: 2005-02-02
Sponsor Name: Kliniken för onkologi, Karolinska Universitetssjukhuset, Solna
Full Title: A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.
Medical condition: Metastatic melanoma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: SE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2004-003516-35 Sponsor Protocol Number: CLINEMAT 66 Start Date: 2005-02-01
Sponsor Name: AZIENDA OSPEDALIERA UMBERTO I
Full Title: Proposal of pilot study for evaluation of Campath-1h activity as second line therapy of mantle cell lymphoma
Medical condition: Second line salvage therapy of relapsed or refractory mantle cell lymphoma
Disease: Version SOC Term Classification Code Term Level
6.1 10026801 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2004-001613-34 Sponsor Protocol Number: 304004 Start Date: 2005-02-01
Sponsor Name: Schering AG
Full Title: A multi-center, double-blind, double-dummy, controlled, randomized study to evaluate cycle control and safety of a four-phasic oral contraceptive containing estradiol valerate and dienogest (SH T00...
Medical condition: Contraception
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: DE (Completed) CZ (Completed)
Trial results: View results

EudraCT Number: 2004-003814-40 Sponsor Protocol Number: FE200486 CS12A Start Date: 2005-02-01
Sponsor Name: Ferring Pharmaceuticals A/S
Full Title: An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer
Medical condition: Prostate Cancer
Disease: Version SOC Term Classification Code Term Level
7.0 10060862 pr t
Population Age: Adults, Elderly Gender: Male
Trial protocol: HU (Completed) DE (Completed)
Trial results: View results
EudraCT Number: 2004-000369-37 Sponsor Protocol Number: NKT102245 Start Date: 2005-02-01
Sponsor Name: GlaxoSmithKline Group of Companies
Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun...
Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed)
Trial results: View results

EudraCT Number: 2004-000587-26 Sponsor Protocol Number: CFTY720A2218E1 Start Date: 2005-02-01
Sponsor Name: Novartis Pharma Services AG
Full Title: A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroid...
Medical condition: Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients
Disease: Version SOC Term Classification Code Term Level
7.0 10023439 LLT
Population Age: Adults Gender: Male, Female
Trial protocol: HU (Completed) DE (Completed) IT (Completed)
Trial results: View results
EudraCT Number: 2004-002255-14 Sponsor Protocol Number: MM17385 Start Date: 2005-02-01
Sponsor Name: F. Hoffmann-La Roche Ltd
Full Title: Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administ...
Medical condition: Study in women with postmenopausal osteoporosis.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) GB (Completed) ES (Completed) DK (Completed)
Trial results: View results

EudraCT Number: 2004-003749-42 Sponsor Protocol Number: EUROPA Start Date: 2005-02-01
Sponsor Name: Enric Pedrol Clotet. Unidad Enfermedades Infecciosas.Hospital de Granollers
Full Title: ESTUDIO DE LOS CAMBIOS EN EL RECUENTO DE LINFOCITOS CD4 TRAS LA SUSTITUCIÓN DE TENOFOVIR POR ABACAVIR EN PACIENTES CON UNA PAUTA HAART QUE INCLUYA DDI + TENOFOVIR Y CON SUPRESIÓN VIRAL
Medical condition: HIV infected patients
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
3